Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.74% | -2.92% | 16.94% | 19.10% | 42.88% |
| Total Depreciation and Amortization | 3.72% | 4.36% | 14.83% | 24.52% | 32.88% |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -100.00% | 168.91% |
| Total Other Non-Cash Items | 389.99% | 308.22% | 551.56% | 169.50% | -130.88% |
| Change in Net Operating Assets | -110.21% | 53.81% | -370.28% | 166.86% | 155.26% |
| Cash from Operations | 7.10% | 22.98% | 25.15% | 35.63% | 46.71% |
| Capital Expenditure | 88.14% | 93.57% | 95.75% | 89.44% | 82.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.10% | -73.27% | -82.22% | -41.61% | -41.27% |
| Cash from Investing | -89.16% | -71.14% | -80.63% | -34.12% | -32.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28,387.55% | 4,136.36% | 2,209.33% | 1,041.76% | -97.12% |
| Repurchase of Common Stock | -270.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 117,420.00% | 5,319.87% | 2,854.48% | 1,341.23% | -99.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.84% | 99.23% | -15.98% | 448.81% | 72.99% |
